1. Home
  2. IRIX vs QTTB Comparison

IRIX vs QTTB Comparison

Compare IRIX & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRIX
  • QTTB
  • Stock Information
  • Founded
  • IRIX 1989
  • QTTB 2015
  • Country
  • IRIX United States
  • QTTB United States
  • Employees
  • IRIX N/A
  • QTTB N/A
  • Industry
  • IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • QTTB Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRIX Health Care
  • QTTB Health Care
  • Exchange
  • IRIX Nasdaq
  • QTTB Nasdaq
  • Market Cap
  • IRIX 20.2M
  • QTTB 23.3M
  • IPO Year
  • IRIX 1996
  • QTTB N/A
  • Fundamental
  • Price
  • IRIX $1.10
  • QTTB $2.19
  • Analyst Decision
  • IRIX
  • QTTB Hold
  • Analyst Count
  • IRIX 0
  • QTTB 7
  • Target Price
  • IRIX N/A
  • QTTB $12.17
  • AVG Volume (30 Days)
  • IRIX 65.6K
  • QTTB 65.7K
  • Earning Date
  • IRIX 11-11-2025
  • QTTB 11-06-2025
  • Dividend Yield
  • IRIX N/A
  • QTTB N/A
  • EPS Growth
  • IRIX N/A
  • QTTB N/A
  • EPS
  • IRIX N/A
  • QTTB N/A
  • Revenue
  • IRIX $49,744,000.00
  • QTTB N/A
  • Revenue This Year
  • IRIX $9.61
  • QTTB N/A
  • Revenue Next Year
  • IRIX N/A
  • QTTB N/A
  • P/E Ratio
  • IRIX N/A
  • QTTB N/A
  • Revenue Growth
  • IRIX 0.09
  • QTTB N/A
  • 52 Week Low
  • IRIX $0.78
  • QTTB $1.35
  • 52 Week High
  • IRIX $1.95
  • QTTB $53.17
  • Technical
  • Relative Strength Index (RSI)
  • IRIX 39.76
  • QTTB 69.18
  • Support Level
  • IRIX $1.09
  • QTTB $1.79
  • Resistance Level
  • IRIX $1.23
  • QTTB $2.11
  • Average True Range (ATR)
  • IRIX 0.08
  • QTTB 0.14
  • MACD
  • IRIX -0.01
  • QTTB 0.04
  • Stochastic Oscillator
  • IRIX 16.18
  • QTTB 81.82

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Share on Social Networks: